Literature DB >> 1740601

Reduced infectivity of cold-adapted influenza A H1N1 viruses in the elderly: correlation with serum and local antibodies.

D C Powers1, B R Murphy, L F Fries, W H Adler, M L Clements.   

Abstract

OBJECTIVE: To compare young and elderly adults in terms of their immune responses and rates of infection following intranasal vaccination with a live attenuated influenza virus.
DESIGN: Time series, comparing outcomes in young and elderly convenience sample.
METHOD: Retrospective laboratory analysis of serum and nasal wash specimens collected during prior studies in which young or elderly volunteers had been inoculated with cold-adapted influenza A/Kawasaki/86 (H1N1) reassortant virus.
SETTING: Johns Hopkins Center for Immunization Research. PARTICIPANTS: Healthy young and elderly adults with pre-vaccination serum hemagglutination inhibition (HAI) antibody titers less than or equal to 1:8. OUTCOME MEASUREMENTS: Antibody responses in serum and nasal washes. MAIN
RESULTS: The proportion of vaccinees who developed any serum or local antibody response was higher in young compared with elderly subjects (20/20 vs 5/14, P less than 0.0005). Resistance to infection with cold-adapted virus correlated with pre-vaccination levels of serum immunoglobulin G (IgG), serum IgA, and nasal wash IgA antibody to whole virus antigen. Age was highly correlated with a lack of response to vaccine by simple regression, but not when data were adjusted for pre-existing antibody levels.
CONCLUSIONS: Cold-adapted reassortant influenza A H1N1 viruses achieve lower rates of infection in elderly than young adults, primarily due to age-related differences in preexisting levels of immunity which may not be reflected by HAI titer.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1740601     DOI: 10.1111/j.1532-5415.1992.tb01938.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  11 in total

1.  Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults.

Authors:  D C Powers; E D Kilbourne; B E Johansson
Journal:  Clin Diagn Lab Immunol       Date:  1996-09

2.  Genetically engineered live attenuated influenza A virus vaccine candidates.

Authors:  N T Parkin; P Chiu; K Coelingh
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

Review 3.  Intranasal cold-adapted influenza virus vaccine combined with inactivated influenza virus vaccines: an extra boost for the elderly?

Authors:  Paul V Targonski; Gregory A Poland
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

4.  Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children.

Authors:  Bruce D Forrest; Michael W Pride; Andrew J Dunning; Maria Rosario Z Capeding; Tawee Chotpitayasunondh; John S Tam; Ruth Rappaport; John H Eldridge; William C Gruber
Journal:  Clin Vaccine Immunol       Date:  2008-04-30

5.  Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers.

Authors:  Iain Stephenson; Maria C Zambon; Anna Rudin; Anthony Colegate; Audino Podda; Roberto Bugarini; Giusseppe Del Giudice; Ada Minutello; Susan Bonnington; Jan Holmgren; Kingston H G Mills; Karl G Nicholson
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

6.  Intramuscular immunization of mice with live influenza virus is more immunogenic and offers greater protection than immunization with inactivated virus.

Authors:  Katie Harris; Rebecca Ream; Jin Gao; Maryna C Eichelberger
Journal:  Virol J       Date:  2011-05-21       Impact factor: 4.099

Review 7.  [Antiviral vaccination and respiratory mucosal immunity: still disappointing results from a seductive idea].

Authors:  F Denis; S Alain; S Hantz; P Lagrange
Journal:  Presse Med       Date:  2005-10-08       Impact factor: 1.228

Review 8.  Respiratory viral infections in the elderly.

Authors:  J Treanor; A Falsey
Journal:  Antiviral Res       Date:  1999-12-15       Impact factor: 5.970

Review 9.  Methodical Design of Viral Vaccines Based on Avant-Garde Nanocarriers: A Multi-Domain Narrative Review.

Authors:  Ehsan Raoufi; Bahar Bahramimeimandi; M Salehi-Shadkami; Patcharida Chaosri; M R Mozafari
Journal:  Biomedicines       Date:  2021-05-06

10.  [Immunity and antiviral vaccinations. Example: the respiratory mucosa].

Authors:  F Denis; S Hantz; S Alain
Journal:  Antibiotiques (Paris)       Date:  2008-01-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.